StockIQpro
NASDAQ:ATRA

Atara Biotherapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Atara Biotherapeutics, Inc.'s revenue fell 6.3% in fiscal 2025 to $120.8M while operating margin rose to 29.7%, its highest in 4 years. Free cash flow was −$50.9M, −42.2% of revenue, and the diluted share count rose 69.8%.Summary generated from Atara Biotherapeutics, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$120.8M
Revenue growth−6.3%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin29.7%
Net margin27.1%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$50.9M
FCF margin−42.2%
Share count change+69.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a649129121
Operating income−340−281−276−8336
Net income−340−228−276−8533
Free cash flow−231−275−194−69−51

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)